|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/09/18 Actinium Pharmaceuticals, Inc. 10-Q 9/30/18 44:2.4M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 324K
2: EX-4.1 Amendment to Actinium Pharmaceuticals, Inc. HTML 17K
Warrant to Purchase Common Stock, Dated November
8, 2018 Issued to Amosan LLC.
3: EX-4.2 Amendment to Actinium Pharmaceuticals, Inc. HTML 17K
Warrant to Purchase Common Stock, Dated November
8, 2018 Issued to Carnegie Hill Partners
4: EX-4.3 Amendment to Actinium Pharmaceuticals, Inc. HTML 17K
Warrant to Purchase Common Stock, Dated November
8, 2018 Issued to Bioche Asset Management, LLC.
5: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
15: R1 Document and Entity Information HTML 42K
16: R2 Consolidated Balance Sheets (Unaudited) HTML 79K
17: R3 Consolidated Balance Sheets (Unaudited) HTML 37K
(Parenthetical)
18: R4 Consolidated Statements of Operations (Unaudited) HTML 53K
19: R5 Consolidated Statements of Cash Flows (Unaudited) HTML 63K
20: R6 Description of Business and Summary of Significant HTML 58K
Accounting Policies
21: R7 Derivative Liabilities HTML 35K
22: R8 Commitments and Contingencies HTML 29K
23: R9 Equity HTML 46K
24: R10 Supplemental Disclosure of Cash Flow Information HTML 17K
25: R11 Subsequent Events HTML 26K
26: R12 Description of Business and Summary of Significant HTML 88K
Accounting Policies (Policies)
27: R13 Description of Business and Summary of Significant HTML 33K
Accounting Policies (Tables)
28: R14 Derivative Liabilities (Tables) HTML 35K
29: R15 Equity (Tables) HTML 35K
30: R16 Description of Business and Summary of Significant HTML 23K
Accounting Policies (Details)
31: R17 Description of Business and Summary of Significant HTML 19K
Accounting Policies (Details 1)
32: R18 Description of Business and Summary of Significant HTML 29K
Accounting Policies (Details 2)
33: R19 Description of Business and Summary of Significant HTML 32K
Accounting Policies (Details Textual)
34: R20 Derivative Liabilities (Details) HTML 22K
35: R21 Derivative Liabilities (Details 1) HTML 36K
36: R22 Derivative Liabilities (Details Textual) HTML 30K
37: R23 Commitments and Contingencies (Details) HTML 46K
38: R24 Equity (Details) HTML 54K
39: R25 Equity (Details 1) HTML 63K
40: R26 Equity (Details Textual) HTML 100K
41: R27 Subsequent Events (Details) HTML 53K
43: XML IDEA XML File -- Filing Summary XML 68K
42: EXCEL IDEA Workbook of Financial Reports XLSX 37K
9: EX-101.INS XBRL Instance -- atnm-20180930 XML 503K
11: EX-101.CAL XBRL Calculations -- atnm-20180930_cal XML 82K
12: EX-101.DEF XBRL Definitions -- atnm-20180930_def XML 324K
13: EX-101.LAB XBRL Labels -- atnm-20180930_lab XML 569K
14: EX-101.PRE XBRL Presentations -- atnm-20180930_pre XML 449K
10: EX-101.SCH XBRL Schema -- atnm-20180930 XSD 93K
44: ZIP XBRL Zipped Folder -- 0001213900-18-015315-xbrl Zip 72K
Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Steve O’Loughlin, certify that:
| 1. | I have reviewed this Form 10-Q of Actinium Pharmaceuticals, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report; |
| 4. | I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have: |
| a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals; | |
| c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| d) | Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| b) | Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: November 9, 2018 | By: | /s/ Steve O’Loughlin |
| Steve O’Loughlin | ||
| Principal Financial Officer | ||
| (Duly Authorized Officer and Principal Financial and Accounting Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/9/18 | None on these Dates | ||
| For Period end: | 9/30/18 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/22 Actinium Pharmaceuticals, Inc. 10-K 12/31/21 56:4.2M EdgarAgents LLC/FA 3/31/21 Actinium Pharmaceuticals, Inc. 10-K 12/31/20 56:3.5M EdgarAgents LLC/FA |